InBrain Pharma

InBrain Pharma is a Paris-based, private biotech developing targeted brain infusion therapies for neurological disorders, with a primary focus on Parkinson's disease. The company leverages a strong scientific foundation from its co-founders and advisors, who are leading neurologists and researchers in movement disorders. While currently pre-revenue and in the pre-clinical/early clinical stage, InBrain is positioning itself in the advanced therapy segment of the neurodegenerative disease market. Its strategy involves overcoming the blood-brain barrier to deliver therapeutics directly to the brain, aiming for superior efficacy and personalized treatment paradigms.

Targeted brain infusion technology for direct delivery of therapeutics to the central nervous system, bypassing the blood-brain barrier. Likely involves device-assisted continuous intracerebral drug delivery systems.

InBrain competes in the advanced Parkinson's disease therapy segment against established device-based treatments like deep brain stimulation (DBS) and pump-delivered therapies (e.g., levodopa-carbidopa intestinal gel, subcutaneous apomorphine). It also competes with numerous biopharma companies developing next-generation oral, injectable, and infused therapies. Its differentiation hinges on proving that direct intracerebral infusion offers a unique efficacy/safety profile for novel therapeutics.